Overview / Abstract: |
Educational Objectives - Discuss atopic dermatitis pathophysiology, focusing on clinically relevant disease mechanisms, risk factors, and novel therapeutic targets - Comprehensively assess patients with atopic dermatitis to determine symptom severity, characterize potential phenotypes, identify comorbidities, and document treatment responses - Describe the clinical profiles of current and emerging biologic therapies for moderate-to-severe atopic dermatitis - Individualize therapy for moderate-to-severe atopic dermatitis to prevent outbreaks, maximize health-related quality of life, manage comorbidities, and minimize treatment-related adverse effects - Communicate with patients and, when necessary, caregivers to improve their understanding of atopic dermatitis and secondary complications, while facilitating shared decision-making Target Audience Statement of Need/Program Overview Physician Accreditation Statement Physician Credit Designation Global Contact Information Instructions to Receive Credit System Requirements MAC Fee Information & Refund/Cancellation Policy Disclosure of Conflicts of Interest The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Robert E. Kalb, MD Grant/Research Support: AbbVie Inc., Amgen Inc., Boehringer-Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., LEO Pharma Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc.; Honoraria: AbbVie Inc., Dermira, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd. Jeffrey M. Weinberg, MD Grant/Research Support: Regeneron Pharmaceuticals, Inc. The following planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Karen Kaufman Nothing to disclose Disclosure of Unlabeled Use The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer |
Expiration |
Jul 01, 2018 |
Discipline(s) |
Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video, Workbook |
Credits / Hours |
1.5 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Robert E. Kalb, MD Jeffrey M. Weinberg, MD |
Sponsors / Supporters / Grant Providers |
This activity is jointly provided by Global Education Group and Integritas Communications. This activity is supported by an educational grant from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals |
Keywords / Search Terms |
Integritas Communications Integritas Communications Integritas Communications Integritas Communications, Dermatology, atopic dermatitis, allergists/clinical immunologist, Free CE, CME Free CE CME Free CE CME Free CE CME |